Cipla Limited (NSE:CIPLA)
India · Delayed Price · Currency is INR 1,363.10
-20.90 (-1.51%)
At close: Sep 9, 2026
Cipla Revenue
Cipla had revenue of 70.77B INR in the quarter ending June 30, 2026, with 3.51% growth. This brings the company's revenue in the last twelve months to 280.68B, up 2.14% year-over-year. In the fiscal year ending March 31, 2026, Cipla had annual revenue of 278.28B with 2.06% growth.
Revenue (ttm)
280.68B
Revenue Growth
+2.14%
P/S Ratio
3.92
Revenue / Employee
8.95M
Employees
31,369
Market Cap
1.10T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 278.28B | 5.60B | 2.06% |
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 349.35B |
| Zydus Lifesciences | 285.92B |
| Glenmark Pharmaceuticals | 177.37B |
| Alkem Laboratories | 150.81B |
| Mankind Pharma | 147.38B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 101.26B |
| Emcure Pharmaceuticals | 96.83B |
Cipla News
- 6 days ago - India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar - Reuters
- 11 days ago - ‘You’re going overboard’: Bombay high court to FDA, restores Cipla’s licence - The Times of India
- 11 days ago - After Bombay HC rap, FDA withdraws orders against Cipla, MCA eateries - The Times of India
- 12 days ago - Maharashtra FDA cancels Cipla unit’s drug sale licences in Pune - The Times of India
- 12 days ago - Maharashtra FDA cancels Pune Cipla facility’s sale licences over ‘lapses’ - The Times of India
- 12 days ago - Misbranding, storage lapses: FDA cancels Cipla Pune unit’s drug licence over Reactin Plus violations - The Times of India
- 5 weeks ago - Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals - Nasdaq
- 6 weeks ago - Cipla Receives FDA Approval For Generic Advair Diskus In All Strengths - Nasdaq